Search Follow us
Refine By

Stock Exchange


Type of Publication


1 - 4 of 4
Sort by: popularity | newest
Page  of 1

A leading remote cardiac monitoring player

Initiation | Pharmaceutical & healthcare | 09 Jan 2017

LifeWatch specialises in ECG-based remote cardiac monitoring services and is one of the leading companies in this space in the US, with around four million patients monitored to date. The company had a solid FY15, with 8.3% adjusted revenue growth and its strongest EBITDA in six years. However, 2016 was turbulent, mainly as a result of costly but one-off legal settlements. Having streamlined its cost base and left the legacy issues behind it, LifeWatch is now well placed to capitalise on healthy market growth, returning to profitability in FY17; we value it at CHF258m ($250m).


Back to the rhythm

QuickView | Pharmaceutical & healthcare | 09 Nov 2016

LifeWatch specialises in ECG-based cardiac monitoring services. Thecompany reported decent adjusted FY15 results delivering revenue growthof 8.3% y-o-y and its strongest adjusted EBITDA in six years. However,2016 turned out to be turbulent, mainly as a result of costly but one-offlegal settlements. Continued good organic growth of the existing serviceoffering and new revenue sources all point to a brighter future.


Maintaining the rhythm

QuickView | Pharmaceutical & healthcare | 29 Jan 2016

A strategic partnership with AliveCor and US (FDA 510k) and EU (CE mark) approvals for the mobile cardiac telemetry (MCT) patch kicks off an important year for LifeWatch. With a full turnaround of the company's fortunes nearly complete, there is a renewed focus on growth via organic and external means. The recent purchase of FlexLife Health and suspension of its home sleep testing services are testament to LifeWatch's new strategic direction.


Established and growing digital health player

QuickView | Pharmaceutical & healthcare | 19 Nov 2015

LifeWatch's remote diagnostic monitoring services provide physicians with critical information to determine appropriate treatment and thereby improve patient outcomes. Digital health is a rapidly advancing sector that is playing an ever important role in the trend towards a more holistic approach to diagnosing, treating and monitoring diseases. LifeWatch specialises in ECG-based cardiac monitoring devices and systems. H115 revenues rose 9.1% to $52.5m, driven by growth in the US market, and the firm posted its best EBIT ($3.8m) and EBITDA ($7.2m) numbers since 2009.